Lupin Introduces Inaugural Biosimilar to Canadian Market

Lupin launches Rymti, its first biosimilar in Canada, through partner Sandoz Canada. Rymti treats various conditions like rheumatoid arthritis, psoriasis, and spondyloarthritis. Approved for all indications of Enbrel, Lupin aims to improve healthcare access and affordability in Canada with Rymti.

Drug firm Lupin on Friday said it has launched its first biosimilar product in Canada.

The company has introduced Rymti through its partner Sandoz Canada, the Mumbai-based drug maker said in a statement.

Rymti is indicated for the treatment of moderate to severe active rheumatoid arthritis, juvenile idiopathic arthritis, active and progressive psoriatic arthritis, severe axial spondyloarthritis, moderate to severe plaque psoriasis and chronic severe plaque psoriasis in children and adolescents.

Rymti is approved for all therapeutic indications of the reference product Enbrel, Lupin stated.

''With this important milestone, we continue to advance healthcare accessibility and affordability for patients in Canada,'' Lupin CEO Vinita Gupta said.